Toxicity of novel anti-hepatitis drug bicyclol: A preclinical study

Table 4 Blood test of female and male beagle dogs in control group before and after bicyclol treatment (mean±SD).

Parameter	Before treatment	After treatment (mo)
		1.5	3	4.5	6	7 (n = 1)
Female (n = 2)
RBC ×1012/L	9.2±0.5	9.2±0.5	7.3±2.2	8.2±0.9	9.8±2.0	8.4
Hb g/L	140±14	140±7	145±7	143±11	148±11	140
RET (%)	0.9±0.3	0.8±0.3	0.9±0.3	0.7±0.3	0.8±0.1	0.6
PLT ×109/L	200±14	205±21	215±35	370±14a	265±78	240
WBC ×109/L	14.6±2.2	13.7±2.0	15.2±3.7	13.6±2.6	16.2±7.2	14.5
Lymphocyte (%)	55±11	55±12	62±14	61±12	69±8	74
Polymorphonuclear leukocyte (%)	41±7	41±13	36±13	34±9	28±4	21
Monocyte (%)	5.5±2.1	5.0±1.4	2.5±0.7	4.0±1.4	3.5±0.7	5
Male (n = 3)
RBC ×1012/L	8.7±1.7	7.3±0.6	8.7±2.1	8.5±1.6	7.9±1.1	8.6
Hb g/L	135±10	140±5	135±9	145±7	150±7	140
RET (%)	0.9±0.4	0.6±0.1	0.6±0.2	0.9±0.4	0.8±0.4	0.8
PLT ×109/L	223±38	250±26	197±32	260±85	290±28	312
WBC ×109/L	12.1±3.1	12.7±0.8	10.6±2.3	11.9±2.1	12.2±1.6	20.1
Lymphocyte (%)	52±12	57±11	48±11	69±4	67±8	66
Polymorphonuclear leukocyte (%)	45±11	39±13	47±10	28±4	26±1	26
Monocyte (%)	3.7±0.6	3.3±1.5	2.7±0.6	3.5±0.7	7.0±1.4a	8

^aP<0.05 vs before dosing.